• 专利标题: APHERESIS TO REDUCE HIGH BLOOD PRESSURE IN PRE-ECLAMPSIA
  • 申请号: US16432771
    申请日: 2019-06-05
  • 公开(公告)号: US20200069861A1
    公开(公告)日: 2020-03-05
  • 发明人: Henry J. Smith
  • 申请人: Henry J. Smith
  • 主分类号: A61M1/36
  • IPC分类号: A61M1/36 A61M1/34
APHERESIS TO REDUCE HIGH BLOOD PRESSURE IN PRE-ECLAMPSIA
摘要:
There are certain factors in the blood of pregnant women with pre-eclampsia that appear to be associated with the disease. These include a soluble variant of the fms-like tyrosine kinase receptor (sFlt-1), soluble Endoglin (sEndoglin), and Endothelin-1. There is also evidence that hypertension may be caused by Na/K ATPase inhibitors such as digitalis-like factor, ouabain-like factors, marinobufogenin and marinobufotoxin. This invention teaches the removal of multiple harmful factors using a combination of targeted apheresis and dialysis and/or ultrafiltration. Harmful factors that are proteins are bound out using immobilized binding agents such as antibodies, aptamers and binding peptides, while small molecule harmful factors are dialyzed out or filtered out. Removal of multiple harmful factors is expected to ameliorate the symptoms of pre-eclampsia and prolong pregnancy.
信息查询
0/0